Iopamiro (Iopamidol)

Iopamidol contains iodine atoms that strongly absorb X‑ray photons. When injected intravenously, it increases the attenuation of X‑rays in the blood and extracellular fluid, producing a radiopaque effect. This contrast between enhanced and non‑enhanced tissues allows clinicians to visualize anatomical details that would otherwise be indistinguishable on standard radiographs.

The dose of Iopamiro is individualized by the prescribing physician based on the specific imaging study, patient body weight, renal function, and the required level of contrast enhancement. Standard dosing guidelines exist, but the final amount administered is always determined by the radiologist or clinician performing the procedure.

Iopamiro is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only if clearly needed. Limited data are available for breastfeeding; a decision should be made after weighing potential benefits against any possible risk to the infant.

To order Iopamiro, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Iopamiro (iopamidol) is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. It provides comparable image quality while reducing the incidence of discomfort and adverse reactions. Compared with other low‑osmolality agents, its physicochemical properties are similar, and choice often depends on institutional preference and specific formulation availability.

Iopamiro should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from moisture and direct sunlight. Do not freeze the product. Before use, inspect the vial for particulate matter or discoloration and ensure the solution is at room temperature to avoid precipitation.

Iopamiro is administered as an intravenous injection or infusion by a qualified healthcare professional. The solution is typically delivered through a peripheral or central vein using a power injector or manual syringe, depending on the imaging protocol. Administration speed and volume are adjusted according to the specific diagnostic procedure.

The most serious risks include severe allergic reactions such as anaphylaxis, contrast‑induced nephropathy leading to acute kidney injury, significant hypotension or cardiovascular collapse, and rare neurological events like seizures. Patients with known iodine hypersensitivity, impaired renal function, or uncontrolled cardiovascular disease require careful assessment before use.

Iopamiro should be avoided in patients with a documented severe allergy to iodinated contrast media, those with uncontrolled asthma or severe bronchospasm, and individuals with markedly impaired renal function where alternative imaging is feasible. Caution is also advised for patients on metformin, as temporary discontinuation may be required to reduce the risk of lactic acidosis.